Kevin Mcculloch Sells 15,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $127,350.00. Following the completion of the transaction, the insider directly owned 1,639,208 shares of the company’s stock, valued at $13,916,875.92. This represents a 0.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, August 3rd, Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.02, for a total value of $120,300.00.
• On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00.

Xeris Biopharma Stock Up 1.8%

Xeris Biopharma stock opened at $8.58 on Thursday. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -78.00 and a beta of 0.70. The stock has a fifty day simple moving average of $8.37 and a two-hundred day simple moving average of $6.96. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares during the last quarter. Millennium Management LLC grew its position in Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the period. Goldman Sachs Group Inc. increased its holdings in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP purchased a new stake in Xeris Biopharma during the first quarter valued at approximately $170,000. 42.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Barclays lifted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.